Hyper-CVAD chemotherapy regimen
Related entities
Findings (27)
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse
None
adverseThe hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.
Effect: adverse